Status:
RECRUITING
Transcranial Ultrasound Stimulation for Cognitive Function Modulation in Patients With Post COVID-19 Brain Fog
Lead Sponsor:
Xuanwu Hospital, Beijing
Conditions:
COVID-19
Brain Fog
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This study aims to investigate whether a specific brain region mediates the cognitive deficit in long COVID brain fog, and whether targeted modulation of this region can improve cognition. In observa...
Eligibility Criteria
Inclusion
- Patients should have a history of COVID-19 infection (positive test results for either polymerase chain reaction or rapid antigen test) and report persistent brain fog (BF) symptoms at least 4 weeks after recovering from acute COVID-19.
Exclusion
- 1\. Presence of any symptoms of cognitive impairment or other neurological symptoms prior to COVID-19 infection;
- 2\. Structural MRI revealing significant intracranial lesions or structural abnormalities;
- 3\. Development of severe neurological complications after COVID-19 infection, including delirium, cerebrovascular diseases, encephalitis, and epilepsy;
- 4\. Other disorders that may cause cognitive impairment, including Dementia, Schizophrenia spectrum disorders, stroke, Alzheimer's disease, and Parkinson's disease.
Key Trial Info
Start Date :
January 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT07154199
Start Date
January 6 2023
End Date
December 1 2027
Last Update
September 4 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100053
2
Shandong Daizhuang Hospital
Jining, Shandong, China